Imovax Polio (Poliovirus (Inactivated) Type 3 (Saukett Strain), Poliovirus (Inactivated) Type 2 (Mef-1 Strain), Po)

The vaccine contains whole poliovirus particles that have been chemically inactivated, preserving their surface antigens. When injected, these antigens stimulate the immune system to produce neutralising antibodies and cellular immunity, which together block infection by live poliovirus if the person is later exposed.

The dosing schedule for Imovax Polio is determined by the prescribing healthcare professional based on age, immunisation history and local public‑health guidelines. The prescriber selects the appropriate number of doses, intervals and route of administration for each patient.

Safety data for Imovax Polio in pregnancy are limited, so the vaccine should only be given when the potential benefit outweighs any theoretical risk. Breastfeeding is not a contraindication, but mothers should discuss vaccination with their obstetrician or paediatrician to make an informed decision.

To place an order, submit an enquiry on the Imovax Polio product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Imovax Polio is an inactivated (killed) vaccine, whereas oral polio vaccine (OPV) uses a live attenuated virus. Inactivated vaccines cannot cause vaccine‑derived poliovirus infection and are preferred in settings where OPV‑related risks must be avoided, such as in immunocompromised individuals or high‑income countries.

Imovax Polio must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Prior to administration, the suspension should be inspected for clarity and particulate matter.

The vaccine is supplied as a sterile suspension for injection. It is administered by a qualified healthcare professional via the intramuscular or subcutaneous route, typically into the deltoid or anterolateral thigh muscle, following the prescribed dosing schedule.

Serious adverse events are rare but include anaphylactic reactions, Guillain‑Barré syndrome, seizures, encephalitis and severe hypotension. Any signs of a severe allergic reaction—such as difficulty breathing, swelling of the face or throat, or a rapid heartbeat—require immediate medical attention.

Individuals with a known severe allergy to any component of the vaccine, including the inactivated virus or stabilisers, should not receive Imovax Polio. Persons with a history of severe anaphylaxis to previous doses of any poliovirus vaccine should also be excluded until evaluated by a specialist.